Program
Tamoxifen
Also written as “tamoxifen”, “Tamoxifen (Nolvadex)” and “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Ovarian Neoplasms, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 80 open or running | phase 3since Sep 30, 2005 | Sep 30, 2005 | none ahead |
| Pfizer | 20 open or running | phase 4since Aug 25, 2010 | May 8, 2002 | none ahead |
| Changchun GeneScience Pharmaceutical | 11 open or running | phase 3since May 31, 2024 | May 31, 2024 | none ahead |
| Daré Bioscience | 10 open or running | phase 2since May 2, 2022 | May 2, 2022 | none ahead |
| Mediclinic Middle East | 10 open or running | phase 2since Mar 14, 2019 | Mar 14, 2019 | none ahead |
| Nalagenetics Pte | 10 open or running | no phasesince Aug 12, 2022 | Aug 12, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 8, 2002First study: phase 3 study in Breast NeoplasmsNew to PfizerPfizer · NCT00036270 · 9,779 enrolled · United States
- Sep 30, 2005AstraZeneca's first study: phase 3 study in Breast NeoplasmsNew to AstraZenecaAstraZeneca · NCT00232661 · 452 enrolled · United States, Belgium, Brazil and more
- Feb 13, 2006Phase 3 study in Breast NeoplasmsAstraZeneca · NCT00291759 · 3,858 enrolled · Austria
- Nov 3, 20084 phase 3 studiesAstraZeneca · NCT00814125, NCT00784940, NCT00784862 and 1 more
- Feb 20, 2009Phase 3 study in Breast NeoplasmsAstraZeneca · NCT00849030 · 9,358 enrolled
- Aug 25, 2010Phase 4 study in PharmacokineticsPfizer · NCT01189500 · 30 enrolled · United States
- Mar 6, 2014Phase 1 study in NeoplasmsAstraZeneca · NCT02093351 · 79 enrolled · Belgium, Denmark, France and more
- Mar 14, 2019Mediclinic Middle East's first study: phase 2 study in Breast Cancer FemaleNew to Mediclinic Middle EastMediclinic Middle East · NCT03879174 · 25 enrolled · United Arab Emirates
- May 2, 2022Daré Bioscience's first study: phase 2 study in Vulvar AtrophyNew to Daré BioscienceDaré Bioscience · NCT05378269 · 17 enrolled · Australia
- Aug 12, 2022Nalagenetics Pte's first study: no phase study in Breast NeoplasmsNew to Nalagenetics PteNalagenetics Pte · NCT05501158 · 150 enrolled · Indonesia
- May 31, 2024Changchun GeneScience Pharmaceutical's first study: phase 3 study in Breast Cancer SubjectsNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT06449027 · 211 enrolled · China
TargetBeta
“Estrogen receptor alpha modulator”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06449027Breast Cancer Subjects · China | 3 | Active, not recruiting | Changchun GeneScience Pharmaceutical | Nov 2025 | 211 |
| NCT05501158Breast Neoplasms · Indonesia | – | UNKNOWN | Nalagenetics Pte | Apr 30, 2024 | 150 |
| NCT05378269Vulvar Atrophy · Australia | 2 | Completed | Daré Bioscience | Dec 20, 2022 | 17 |
| NCT03879174Breast Cancer Female · United Arab Emirates | 2 | UNKNOWN | Mediclinic Middle East | Aug 1, 2022 | 25 |
| NCT02093351Neoplasms · Belgium, Denmark, France and more | 1 | Completed | AstraZeneca | Apr 30, 2015 | 79 |
| NCT01189500Pharmacokinetics · United States | 4 | Completed | Pfizer | Oct 2010 | 30 |
| NCT00849030Breast Neoplasms | 3 | Completed | AstraZeneca | Jun 2001 | 9,358 |
| NCT00814125Breast Neoplasms | 3 | Completed | AstraZeneca | 285 | |
| NCT00784940Bone Density | 3 | Completed | AstraZeneca | Mar 2005 | 308 |
| NCT00784862Breast Neoplasms | 3 | Completed | AstraZeneca | 9,358 | |
| NCT00784680Quality of Life | 3 | Completed | AstraZeneca | 308 | |
| NCT00291759Breast Neoplasms · Austria | 3 | Completed | AstraZeneca | Jun 2009 | 3,858 |
| NCT00232661Breast Neoplasms · United States, Belgium, Brazil and more | 3 | Completed | AstraZeneca | Jan 2003 | 452 |
| NCT00036270Breast Neoplasms · United States | 3 | Completed | Pfizer | Oct 2008 | 9,779 |
How it is read
Names in the registry
- “Tamoxifen”, 11 entries
- “tamoxifen”, 2 entries
- “Tamoxifen (Nolvadex)”, 2 entries
- “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”, 1 entry
- “T Leuprolide Injectable Emulsion”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 14 studies
- Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.